Tags

Type your tag names separated by a space and hit enter

Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS).
Schizophr Res 2010; 124(1-3):36-42SR

Abstract

As part of an ongoing scale development process, this study provides an initial examination of the psychometric properties and validity of a new interview-based negative symptom instrument, the Clinical Assessment Interview for Negative Symptoms (CAINS), in outpatients with schizophrenia or schizoaffective disorder (N = 37). The scale was designed to address limitations of existing measures and to comprehensively assess five consensus-based negative symptoms: asociality, avolition, anhedonia (consummatory and anticipatory), affective flattening, and alogia. Results indicated satisfactory internal consistency reliability for the total CAINS scale score and promising inter-rater agreement, with clear areas identified in need of improvement. Convergent validity was evident in general agreement between the CAINS and alternative negative symptom measures. Further, CAINS subscales significantly correlated with relevant self-report emotional experience measures as well as with social functioning. Discriminant validity of the CAINS was strongly supported by its small, non-significant relations with positive symptoms, general psychiatric symptoms, and depression. These preliminary data on an early beta-version of the CAINS provide initial support for this new assessment approach to negative symptoms and suggest directions for further scale development.

Authors+Show Affiliations

University of Maryland, College Park, MD 20742-4411, United States.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Validation Studies

Language

eng

PubMed ID

20869848

Citation

Forbes, Courtney, et al. "Initial Development and Preliminary Validation of a New Negative Symptom Measure: the Clinical Assessment Interview for Negative Symptoms (CAINS)." Schizophrenia Research, vol. 124, no. 1-3, 2010, pp. 36-42.
Forbes C, Blanchard JJ, Bennett M, et al. Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr Res. 2010;124(1-3):36-42.
Forbes, C., Blanchard, J. J., Bennett, M., Horan, W. P., Kring, A., & Gur, R. (2010). Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophrenia Research, 124(1-3), pp. 36-42. doi:10.1016/j.schres.2010.08.039.
Forbes C, et al. Initial Development and Preliminary Validation of a New Negative Symptom Measure: the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr Res. 2010;124(1-3):36-42. PubMed PMID: 20869848.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS). AU - Forbes,Courtney, AU - Blanchard,Jack J, AU - Bennett,Melanie, AU - Horan,William P, AU - Kring,Ann, AU - Gur,Raquel, Y1 - 2010/09/24/ PY - 2010/07/02/received PY - 2010/08/23/revised PY - 2010/08/27/accepted PY - 2010/9/28/entrez PY - 2010/9/28/pubmed PY - 2011/4/20/medline SP - 36 EP - 42 JF - Schizophrenia research JO - Schizophr. Res. VL - 124 IS - 1-3 N2 - As part of an ongoing scale development process, this study provides an initial examination of the psychometric properties and validity of a new interview-based negative symptom instrument, the Clinical Assessment Interview for Negative Symptoms (CAINS), in outpatients with schizophrenia or schizoaffective disorder (N = 37). The scale was designed to address limitations of existing measures and to comprehensively assess five consensus-based negative symptoms: asociality, avolition, anhedonia (consummatory and anticipatory), affective flattening, and alogia. Results indicated satisfactory internal consistency reliability for the total CAINS scale score and promising inter-rater agreement, with clear areas identified in need of improvement. Convergent validity was evident in general agreement between the CAINS and alternative negative symptom measures. Further, CAINS subscales significantly correlated with relevant self-report emotional experience measures as well as with social functioning. Discriminant validity of the CAINS was strongly supported by its small, non-significant relations with positive symptoms, general psychiatric symptoms, and depression. These preliminary data on an early beta-version of the CAINS provide initial support for this new assessment approach to negative symptoms and suggest directions for further scale development. SN - 1573-2509 UR - https://www.unboundmedicine.com/medline/citation/20869848/Initial_development_and_preliminary_validation_of_a_new_negative_symptom_measure:_the_Clinical_Assessment_Interview_for_Negative_Symptoms__CAINS__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0920-9964(10)01511-2 DB - PRIME DP - Unbound Medicine ER -